RecruitingPhase 3NCT05914155

Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome

Studying Non-genetic systemic disease with glomerulopathy as a major feature

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shoichi Maruyama MD PhD
Principal Investigator
Shoichi Shoichi, PhD, MD
Nagoya University Hospital
Intervention
Rituximab (genetical recombination)(drug)
Enrollment
88 enrolled
Eligibility
15 years · All sexes
Timeline
20232027

Study locations (18)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05914155 on ClinicalTrials.gov

Other trials for Non-genetic systemic disease with glomerulopathy as a major feature

Additional recruiting or active studies for the same condition.

See all trials for Non-genetic systemic disease with glomerulopathy as a major feature

← Back to all trials